Featured

Status

All Statuses
  • Withdrawn54

Health Topics

Any Category
Clear Filters

Search Clinical Trials

54 Results
Withdrawn
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
Earlier, healthy donors gave blood for us to make CD30.CAR-EBVST cells in the laboratory. These cells were grown and frozen and the investigators will select the donor which the investigators …
Baylor Role: Lead Sponsor
Withdrawn
Mesenchymal Stem Cells for Age-Related Frailty
Frailty is an aging-related syndrome of impaired physiologic reserve and function across multiple organs, leading to increased vulnerability for adverse health outcomes. Frailty is associated with an increased risk for …
Baylor Role: Collaborator
Withdrawn
Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept
More treatments are needed to target insomnia in Veterans with Posttraumatic Stress Disorder. There is evidence to suggest that pimavanserin, a medication approved by the Food and Drug Administration for …
Baylor Role: Lead Sponsor
Withdrawn
Azacytidine During Anti-tuberculosis Therapy
All study participants will have drug-sensitive TB and successfully complete 2 months of standard intensive phase 4-drug RHZE (rifampin, isoniazid, pyrazinamide, ethambutol). By definition, to have uncomplicated TB, participants will …
Withdrawn
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
First, a donor gave us blood to make CD19 chimeric receptor multivirus specific T cells in the laboratory. These cells are grown and frozen for the patient. To make these …
Baylor Role: Lead Sponsor
Withdrawn
Nitric Oxide During CPB to Reduce AKI in Neonates
Screening: All patients undergoing either elective or emergency cardiac surgery will be screened against the eligibility criteria. Research Sample Collection: Blood and urine will be collected for the first 48 …
Withdrawn
Peppermint Oil Pharmacokinetics/Dynamics
An initial single-dose PK study will be carried out. Forty-two children (n=21 per dose) will be randomized to receive approximately 10.9 mg·kg-1·d-1 of PMO or to receive approximately 18.2 mg·kg-1·d-1 …
Baylor Role: Lead Sponsor
Withdrawn
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
A maximum of 42 subjects will participate in the treatment part of this study. The investigators will collect up to 180 mL of the participants blood. The investigators will use …
Baylor Role: Lead Sponsor
Withdrawn
Zonisamide Outpatient Study
This is a randomized, double-blind, placebo-controlled study to examine the ability of 5-weeks treatment with zonisamide to reduce symptoms of PTSD and AUD. The study population will consist of 60 …
Baylor Role: Collaborator
Withdrawn
Tranexamic Acid in Adherent Placenta (TAP)
This trial is a randomized, double blind, placebo controlled trial to quantify the effects of the preoperative administration of tranexamic acid on estimated blood loss and blood product utilization in …
Baylor Role: Lead Sponsor